Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Real-world study of bispecific T-cell engager safety and efficacy in systemic AL amyloidosis finds heme ORR 76% (66% CR, 7% VGPR), MRD-negative in 6/6 tested, cardiac and renal response in 64% and 100%; CRS in 45% (all G 1/2).”
Title: The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis
Authors: Matthew J. Rees, Jack Khouri, Ariel F. Grajales-Cruz, Saurabh S. Zanwar, Utkarsh Goel, Shonali Midha, Julian Kelley, Omar Castaneda Puglianini, Andre De Menezes Silva Corraes, Shahzad Raza, James A. Davis, Kimberly Green, Doris K. Hansen, Rahul Banerjee, Surbhi Sidana, Krina K. Patel, Giada Bianchi, Douglas W. Sborov, Sarah Lee, Shaji K. Kumar, Rachid Baz, Faiz Anwer, Lekha Mikkilineni, Omar Nadeem, Yi Lin, Larry D. Anderson Jr
You can read the Full Article in the American Journal of Hematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
